| 臺大學術典藏 |
2020-04-27T08:45:05Z |
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment
|
Lu S.-L.;Hsu F.-M.;Tsai C.-L.;Lee J.-M.;Huang P.-M.;Hsu C.-H.;Lin C.-C.;Chang Y.-L.;Hsieh M.-S.;Chia-Hsien Cheng; Lu S.-L.; Hsu F.-M.; Tsai C.-L.; Lee J.-M.; Huang P.-M.; Hsu C.-H.; Lin C.-C.; Chang Y.-L.; Hsieh M.-S.; CHIA-HSIEN CHENG |
| 臺大學術典藏 |
2020-04-24T08:53:16Z |
Growth and characterization of CdSe nanoneedles and other one-dimensional CdSe nanostructures
|
Cheng, J.H.; Chao, H.Y.; Chang, Y.H.; Hsu, C.H.; Cheng, C.L.; Chen, T.T.; Chen, Y.F.; Chu, M.W. |
| 臺大學術典藏 |
2020-04-24T08:53:13Z |
Growth and characterization of oriented CdSe nanobelts and nanorods
|
Cheng, J.H.; Chao, H.Y.; Chang, Y.H.; Hsu, C.H.; Cheng, C.L.; Chu, M.-W.; Chen, Y.F. |
| 臺大學術典藏 |
2020-04-21T03:52:07Z |
Enhancement of thermoelectric figure of merit in β -Zn4Sb3 by indium doping control
|
Chen, Y. Y.; Wei, P. C.; Yang, C. C.; Chen, J. L.; Sankar, R.; Chen, C. L.; Hsu, C. H.; Chang, C. C.; Chen, C. L.; Dong, C. L.; Chou, F. C.; Chen, K. H.; Wu, M. K. |
| 臺大學術典藏 |
2020-04-16T02:35:00Z |
Mobile nursing cart with software defined radio for healthcare enterprises
|
Hsu, C.-H.;Hsieh, S.-H.;Hsu, J.-T.;Cheng, P.-H.;Chen, S.-J.;Lai, F.-P.; Hsu, C.-H.; Hsieh, S.-H.; Hsu, J.-T.; Cheng, P.-H.; Chen, S.-J.; Lai, F.-P.; FEI-PEI LAI |
| 臺大學術典藏 |
2020-04-16T02:35:00Z |
Ubiquitous mobile personal health system based on cloud computing
|
Hsu, J.-T.; Hsieh, S.-H.; Lo, C.-C.; Hsu, C.-H.; Cheng, P.-H.; Chen, S.-J.; Lai, F.-P.; FEI-PEI LAI; Hsu, J.-T.;Hsieh, S.-H.;Lo, C.-C.;Hsu, C.-H.;Cheng, P.-H.;Chen, S.-J.;Lai, F.-P. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Chen L.-T.; Shiah H.-S.;Cheng A.-L.;Chiun Hsu;Hsu C.-H.;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Chiun Hsu; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Yang C.-H.; Cheng A.-L.; Lin C.-C.;Chiun Hsu;Hsu C.-H.;Hsu W.-L.;Cheng A.-L.;Yang C.-H.; Lin C.-C.; Chiun Hsu; Hsu C.-H.; Hsu W.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:24Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Yang C.-H.; Chiun Hsu; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Lin C.-C.; Lin C.-C.;Yeh K.-H.;Yang C.-H.;Chiun Hsu;Tsai Y.-C.;Hsu W.-L.;Cheng A.-L.;Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:23Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Yang C.-H.; Yang P.-C.; Cheng A.-L.; Lin C.-C.; Hsu C.-H.; Yu C.-J.; Chang Y.-C.; Chiun Hsu; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; Chiun Hsu; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Kuo S.-H.;Chiun Hsu;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Chiun Hsu; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:20Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:19Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:17Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.;Lin Z.-Z.;Chiun Hsu;Shen Y.-C.;Hsu C.-H.;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:16Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Chiun Hsu ;Shen Y.-C. ;Hsu C.-H. ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:16Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-H.; Hu F.-C.; Hsu C.-Y. ;Shen Y.-C. ;Yu C.-W. ;Chiun Hsu ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Chiun Hsu; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Chiun Hsu; Hsu C.-H.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:14Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Chiun Hsu; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Cheng A.-L.; Yeh K.-H.; Chiun Hsu; Cheng W.-F.; Lin Y.-L.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:04Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Shih T.T.-F.; Cheng A.-L.; Hsu C.-H.; Chiun Hsu; Liang P.-C.; Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Chiun Hsu;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; Yu C.-W. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.;Kuo T.-C.;Wu H.;Guo J.-C.;Chiun Hsu;Hsu C.-H.;Tien Y.-W.;Yeh K.-H.;Cheng A.-L.;Kuo S.-H.; Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Chiun Hsu; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Chiun Hsu;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Chiun Hsu; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-04-10T12:16:14Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.; Ding Y.-H.; YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
YU-YUN SHAO; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
YU-YUN SHAO; Lu L.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma
|
Cheng A.-L.; YU-YUN SHAO; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; Hsu C.; Cheng W.-F.; Hsu C.-H.; YU-YUN SHAO; Lu L.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy
|
YU-YUN SHAO; Huang C.-C.; Lin S.-D.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma
|
Chang Y.-L.; YU-YUN SHAO; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lu L.-C.;Yu-Yun Shao;Lee Y.-H.;Hsieh M.-S.;Hsiao C.-H.;Lin H.-H.;Kao H.-F.;Ma Y.-Y.;Yen F.-C.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; YU-YUN SHAO; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
Lu L.-C.;Yu-Yun Shao;Chan S.-Y.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; YU-YUN SHAO; Chan S.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases
|
Yu-Yun Shao;Ho M.-C.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Ho M.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:06Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Yen F.-C.; Hsu C.-H.; Cheng A.-L.; YU-YUN SHAO; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yu-Yun Shao;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Hsu C.-H.;Cheng A.-L. |
